| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID6222: Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease |
|
Medicine details |
|
| Medicine name | donanemab (Kisunla®) |
| Formulation | Intravenous infusion |
| Reference number | 5156 |
| Indication | Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E e 4 (ApoE e 4) heterozygotes or non-carriers |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| NICE guidance | |